Cagrilintide

Cagrilintide is a long-acting synthetic analog of human amylin — the 37-amino-acid peptide co-secreted with insulin from pancreatic β-cells. Novo Nordisk engineered it with residue substitutions for stability and a C16 fatty-diacid side chain that binds albumin, stretching the half-life from amylin's native ~13 minutes to roughly 7–8 days and enabling once-weekly subcutaneous dosing. Functionally it's a dual amylin/calcitonin receptor agonist (DACRA) — it hits all three amylin receptor subtypes (AMY1R, AMY2R, AMY3R, which are heterodimers of the calcitonin receptor with RAMP1/2/3) plus the calcitonin receptor itself. The practical upshot: durable, centrally-mediated appetite suppression that works through a pathway entirely separate from GLP-1.

Central Appetite Suppression via Hindbrain Amylin Receptors#

The dominant mechanism is not peripheral — it's CNS. Cagrilintide crosses into circumventricular organs (notably the area postrema and nucleus tractus solitarius in the hindbrain) and engages amylin receptors that project into hypothalamic feeding circuits. Activation drives satiety, reduces meal size, and extends inter-meal intervals. Receptor-knockout work has mapped this effect cleanly:

"The anorectic and weight-lowering effects of cagrilintide are mediated primarily via amylin receptors 1 and 3 in the hindbrain and hypothalamus." — Larsen AT, Mohamed KA, Sonne N, et al. eBioMedicine, 2025

Ablating AMY1R and AMY3R abolishes the weight-loss response, confirming that the compound is not working primarily through gut signaling or direct metabolic effects. This is why users feel the effect as reduced food noise and earlier fullness cues rather than as nausea-driven aversion (though nausea certainly shows up during titration).

Delayed Gastric Emptying and Postprandial Glucagon Suppression#

Amylin receptor activation also slows gastric emptying and blunts the postprandial glucagon spike. Slowed emptying extends mechanical stretch signaling from the stomach — reinforcing the central satiety signal and flattening post-meal glucose excursions. Glucagon suppression reduces hepatic glucose output, which matters less for lean physique-focused users but contributes to the HbA1c improvements seen in the T2D trials.

The practical translation for a cutting protocol: smaller portions feel satisfying for longer, and the late-night "I need to eat something" urge is dramatically attenuated. The trade-off is that alcohol and large high-fat meals sit heavy — delayed emptying is a feature in a calorie deficit and a liability at a restaurant.

Pharmacokinetics — Why Once-Weekly Works#

The albumin-binding diacid tail is what makes this a viable weekly protocol rather than a daily injection like native amylin or pramlintide. Phase 1b work characterized the PK cleanly across the full dose range:

"Cagrilintide exhibited a half-life of 159–195 h and dose-proportional pharmacokinetics supporting once-weekly dosing; gastrointestinal events were the most common adverse events during dose escalation." — Enebo LB, Berthelsen KK, Kankam M, et al. Lancet, 2021

Steady state lands around week 5–6. The long half-life is also why rushed titration punishes users — the dose you injected last Monday is still sitting near its peak when you inject the next one. Doubling every 2 weeks is a recipe for a miserable month; every 4 weeks is the protocol the trials used and what the community has converged on.

Orthogonal to GLP-1 — The Mechanistic Basis for CagriSema#

Cagrilintide's appetite suppression runs through amylinergic CNS circuits. Semaglutide, tirzepatide, and retatrutide run through GLP-1 (and GIP, and glucagon) receptors in partially overlapping but distinct brain regions. Because the two signaling systems converge on feeding behavior from different receptor families, their effects stack rather than plateau:

"CagriSema resulted in a mean bodyweight reduction of 15.6% at week 32 compared with 8.1% with semaglutide alone." — Frías JP, Deenadayalan S, Erichsen L, et al. Lancet, 2023

This is the whole rationale for the DIY CagriSema protocol and why adding 0.5–1.2 mg cagri to a stalled semaglutide run frequently restarts fat loss without escalating the GLP-1 dose further. It's also why the combination is substantially more potent than either monotherapy — and why the GI side effect burden compounds, so titrating one compound at a time is non-negotiable.

What It Is Not#

Cagrilintide does not touch the HPTA, androgen receptors, or muscle protein synthesis pathways. It is a pure appetite and satiety tool — the fat loss it produces is driven entirely by the calorie deficit it makes easy to adhere to. Lean mass preservation is still on you: protein intake, resistance training, and (if the goal is recomp) an androgen base do the muscle-sparing work. Cagri just removes the hunger that makes a deficit hard to hold for 20+ weeks.

Common (most users)#

GI dominates the side-effect profile — this is an amylin analog that delays gastric emptying and activates hindbrain satiety circuits, so your gut is going to notice. Most of it is manageable with slow titration.

• Nausea — the headline complaint, worst in the 24–48h window after injection during dose escalations. Mitigation: titrate slowly (double roughly every 4 weeks, not every 2), inject in the evening so you sleep through the peak, keep meals smaller and lower-fat on injection day, and hold the current dose for an extra 2–4 weeks rather than pushing through. Ginger and ondansetron both work if it gets rough.
• Decreased appetite — by design, but some users drop intake so low they under-eat protein and lose lean mass. Mitigation: force-feed ≥1 g protein/lb LBM even when you're not hungry; lean on protein shakes, Greek yogurt, and low-volume high-protein foods when solid meals feel impossible.
• Constipation — delayed gastric emptying plus reduced food volume equals sluggish transit. Mitigation: 3+ L water daily, psyllium or magnesium citrate at night, keep fiber reasonable (not heroic — too much fiber on a cagri gut makes things worse).
• Early satiety / "food noise" gone — not really a side effect, but users often describe it as unsettling. The upside of the same mechanism.
• Fatigue during titration — usually resolves within a week of reaching a stable dose. Mitigation: check you're not just under-eating calories; 500+ kcal daily deficits plus cagri will flatten anyone.
• Injection-site reactions — mild erythema or itching in ~10–15%. Rotate sites (abdomen, flank, thigh).

"Cagrilintide exhibited a half-life of 159–195 h and dose-proportional pharmacokinetics supporting once-weekly dosing; gastrointestinal events were the most common adverse events during dose escalation." — Enebo et al., Lancet (2021)

Uncommon (dose-dependent or individual)#

• Vomiting / dyspepsia / reflux — shows up at 1.7–2.4 mg in susceptible users, especially after large or fatty meals. Back off half a dose step and hold for 4 weeks. Alcohol + big dinner + cagri reliably produces a miserable evening — plan accordingly.
• Diarrhea — less common than constipation but happens. Usually self-limiting; if persistent, drop back a dose tier.
• Mild resting HR elevation — a few bpm, reported across amylin analog trials. Check resting HR and BP at baseline and 12 weeks. Not clinically meaningful for most, but worth logging if you're stacking with other stimulants or on cycle.
• Hypoglycemia — uncommon on cagri monotherapy, but meaningful when stacked with insulin, sulfonylureas, or aggressive GLP-1 dosing in a deep deficit. Check fasted glucose; eat on a schedule even when appetite is gone.
• Lean mass loss with rapid weight drop — not a "side effect" in the pharmacological sense, but the single most common regret. On CagriSema protocols, 25–40% of total weight lost can be lean mass if protein and resistance training are neglected. The fix is boring and non-negotiable: 1 g protein/lb LBM, lift 3–5×/week, don't run deficits bigger than ~500–750 kcal.

"A total of 72.5% of patients receiving CagriSema reported gastrointestinal adverse events compared with 34.4% in the placebo group, with most being mild or moderate in severity." — Davies et al., NEJM (2025)

Rare but serious#

• Gallstones / cholecystitis — a class effect of any potent anorectic producing rapid weight loss, not cagri-specific. Warning signs: RUQ pain especially after fatty meals, nausea disproportionate to dose, referred shoulder pain. Stop and image if symptoms appear.
• Pancreatitis — uncommon but reported across the GLP-1/amylin weight-loss space. Warning signs: severe epigastric pain radiating to the back, persistent vomiting. Stop immediately, get lipase drawn.
• Severe / persistent vomiting leading to dehydration — mostly in users who ignored the titration schedule. Stop, hydrate, restart one tier lower.
• Hypersensitivity reactions — rare with peptide therapeutics but possible. Stop on any urticaria, angioedema, or systemic reaction.

Hard contraindications#

• Pregnancy and lactation — do not use.
• Active gastroparesis — cagri delays gastric emptying by mechanism; it will make gastroparesis worse.
• Active pancreatitis or recent pancreatitis history — do not use.
• Known hypersensitivity to amylin analogs (pramlintide, cagrilintide).
• Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome — this is the GLP-1 boxed warning, not an amylin one, but it applies fully to any CagriSema stack (i.e. any protocol where cagri is combined with semaglutide, tirzepatide, or retatrutide).
• Concurrent use with insulin on a fasted-training / skipped-meals schedule — the delayed gastric emptying plus exogenous insulin is a reliable way to bottom out glucose. When both are used, maintain a fixed eating schedule and monitor fingerstick glucose.

Gender and PCT considerations#

Cagrilintide has no androgenic, estrogenic, or HPTA activity — it's a non-hormonal satiety peptide. Women use identical dosing with no virilization concern and no cycle-timing issues. No PCT required. The only sex-specific line is pregnancy/lactation, which is a hard stop for any weight-loss pharmacology regardless of class. Men running AAS alongside a cut can stack cagri freely; it won't interact with your hormonal protocol, and a TRT-dose testosterone base is arguably the single best lean-mass insurance policy on an aggressive CagriSema-driven deficit.